Sarepta (SRPT) Trades Higher on Eteplirsen Phase II Update, Analyst Comments

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. USO
2. CHRW
3. MRVL
4. AMD
5. RXO
6. OPCH
7. NVDA
8. LW
9. GOOGL
10. APLD

Go back to Sarepta (SRPT) Trades Higher on Eteplirsen Phase II Update, Analyst Comments

Sarepta (SRPT) Analysts Split on Accelerated Eteplirsen Approval - Barron's

March 25, 2013 2:51 PM EDT

Sarepta Therapeutics (Nasdaq: SRPT) is comfortably in positive territory Monday following positive commentary in Barron's over the weekend.

Traders and investors are watching Sarepta as the FDA nears a decision on its Duchenne muscular dystrophy (DMD) drug, eteplirsen. Shares of Sarepta have traded strong since positive results from a Phase 2B trial on DMD were released last October.
... More

Sarepta (SRPT) Analysts Split on Accelerated Eteplirsen Approval - Barron's

March 25, 2013 2:51 PM EDT

Sarepta Therapeutics (Nasdaq: SRPT) is comfortably in positive territory Monday following positive commentary in Barron's over the weekend.

Traders and investors are watching Sarepta as the FDA nears a decision on its Duchenne muscular dystrophy (DMD) drug, eteplirsen. Shares of Sarepta have traded strong since positive results from a Phase 2B trial on DMD were released last October.
... More

Buzz on Sarepta's Eteplirsen From London Duchenne Meeting

Duchenne muscular dystrophy (DMD) patients treated with Sarepta Therapeutics' (SRPT) eteplirsen continue to do well on...